[针对多发性骨髓瘤的双特异性抗体的发展和前景]
1Department of Hematology and Experimental Therapeutics/ Hematological Treatment Development Promotion Office, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East.
[Rinsho ketsueki] The Japanese journal of clinical hematology
|October 2, 2024
概括
针对BCMA,GPRC5D和FcRH5的两种特异性抗体对耐火性多发性髓瘤显示出有前途. 然而,包括抗原损失和免疫因素在内的耐药性机制需要进一步研究,以改善患者的治疗结果.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 三级耐火性多发性骨髓瘤在历史上有着不良的预后.
- 针对BCMA,GPRC5D和FcRH5的双特异性抗体 (bsAbs) 提供了新的治疗选择.
研究的目的:
- 审查对多发性骨髓瘤的双特异性抗体的发展.
- 讨论对双特异性抗体疗法的耐药性机制.
主要方法:
- 在多发性髓瘤中对双特异性抗体的文献综述.
- 对抗性机制的分析,包括瘤内在因素和免疫介导因素.
主要成果:
- 双特异性抗体在耐火性多发性髓瘤中表现出显著的临床活性.
- 对bsAbs的耐药性可能来自瘤内在因素,如抗原损失或免疫依赖因素.
结论:
- 双特异性抗体代表了多发性骨髓瘤治疗的有希望的进步.
- 了解抵抗机制对于优化bsAbs治疗和改善患者反应至关重要.
相关概念视频
01:31Hybridoma Technology
14.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.1K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K